RIL
CMPX icon

Rothschild Investment LLC’s Compass Therapeutics CMPX Stock Holding History

Rothschild Investment LLC’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.68K Buy
765
+486
+174% +$1.44K ﹤0.01% 2829
2026
Q1 		$1.48K Buy
279
+115
+70% +$664 ﹤0.01% 2696
2025
Q4 		$881 Buy
164
+44
+37% +$203 ﹤0.01% 2722
2025
Q3 		$420 Hold
120
– – ﹤0.01% 2870
2025
Q2 		$312 Buy
+120
New +$247 ﹤0.01% 2852

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Rothschild Investment LLC's CMPX Position: Q2 2026 in Review

Rothschild Investment LLC increased its Compass Therapeutics (CMPX) stake by 174% in Q2 2026, buying an estimated $1.44K and bringing the position to 765 shares worth $1.68K. The position accounts for ﹤0.01% of the portfolio, ranked #2829.

Rothschild Investment LLC first reported a position in CMPX in Q2 2025 and has held it in 5 quarters since. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Rothschild Investment LLC held 765 shares of Compass Therapeutics worth $1.68K as of Q2 2026.
  • Rothschild Investment LLC bought 486 Compass Therapeutics shares in Q2 2026, an estimated $1.44K.
  • Compass Therapeutics made up ﹤0.01% of Rothschild Investment LLC's portfolio in Q2 2026, its #2829 holding.
  • Rothschild Investment LLC first reported a position in Compass Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Rothschild Investment LLC's 13F filing for Q2 2026, filed 6 Aug 2026.